Metagenomi, Inc. (NASDAQ:MGX – Get Free Report) has earned a consensus rating of “Moderate Buy” from the seven analysts that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $16.67.
Several research firms have weighed in on MGX. HC Wainwright increased their price objective on Metagenomi from $7.00 to $14.00 and gave the stock a “buy” rating in a report on Tuesday, December 10th. Chardan Capital reaffirmed a “buy” rating and issued a $15.00 price target on shares of Metagenomi in a research note on Wednesday, November 20th.
View Our Latest Research Report on Metagenomi
Institutional Inflows and Outflows
Metagenomi Price Performance
NASDAQ MGX opened at $3.61 on Monday. Metagenomi has a 1 year low of $1.61 and a 1 year high of $12.74. The business’s 50-day moving average is $2.60 and its 200 day moving average is $3.01.
About Metagenomi
Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.
Read More
- Five stocks we like better than Metagenomi
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Work and Play: Investing in the Rise of Bleisure Travel
- What Are Growth Stocks and Investing in Them
- Top Dividend Stocks to Buy Now as Bond Yields Could Lower
- Stock Average Calculator
- SAP: AI Tailwinds Accelerating Enterprise Cloud Business
Receive News & Ratings for Metagenomi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metagenomi and related companies with MarketBeat.com's FREE daily email newsletter.